Shares of Chemours Co (NYSE:CC) have been given an average recommendation of “Buy” by the ten analysts that are currently covering the stock. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokers that have covered the stock in the last year is $32.08.

Several research firms have issued reports on CC. Citigroup Inc boosted their price objective on Chemours from $62.00 to $63.00 and gave the stock a “buy” rating in a report on Monday. Jefferies Group LLC upgraded Chemours from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $35.00 to $48.00 in a report on Wednesday, March 29th. Susquehanna Bancshares Inc upgraded Chemours from a “neutral” rating to a “positive” rating and set a $40.00 price objective on the stock in a report on Friday, February 17th. Zacks Investment Research upgraded Chemours from a “hold” rating to a “strong-buy” rating and set a $38.00 price objective on the stock in a report on Thursday, February 16th. Finally, Goldman Sachs Group Inc upgraded Chemours from a “neutral” rating to a “buy” rating in a report on Monday, February 13th. They noted that the move was a valuation call.

Shares of Chemours (NYSE:CC) traded up 1.19% during mid-day trading on Tuesday, hitting $37.53. 2,404,607 shares of the company traded hands. Chemours has a 52-week low of $5.82 and a 52-week high of $39.02. The firm has a market cap of $6.87 billion, a price-to-earnings ratio of 962.31 and a beta of 3.50. The firm has a 50-day moving average price of $35.43 and a 200 day moving average price of $26.37.

Chemours (NYSE:CC) last posted its quarterly earnings data on Wednesday, February 15th. The specialty chemicals company reported $0.08 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.29 by $0.21. The company had revenue of $1.30 billion for the quarter, compared to analyst estimates of $1.24 billion. Chemours had a return on equity of 81.19% and a net margin of 2.78%. Equities research analysts anticipate that Chemours will post $2.69 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Chemours Co (CC) Receives $32.08 Consensus Target Price from Brokerages” was first posted by Financial Market News and is the property of of Financial Market News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international trademark & copyright law. The legal version of this piece of content can be read at http://www.financial-market-news.com/chemours-co-cc-receives-32-08-consensus-target-price-from-brokerages/1406427/.

A number of institutional investors have recently added to or reduced their stakes in the company. BlackRock Fund Advisors increased its position in Chemours by 7.7% in the third quarter. BlackRock Fund Advisors now owns 13,116,695 shares of the specialty chemicals company’s stock worth $209,867,000 after buying an additional 934,559 shares in the last quarter. FMR LLC increased its position in Chemours by 481.3% in the fourth quarter. FMR LLC now owns 10,926,459 shares of the specialty chemicals company’s stock worth $241,366,000 after buying an additional 9,046,728 shares in the last quarter. Norges Bank purchased a new position in Chemours during the fourth quarter worth approximately $196,709,000. BlackRock Institutional Trust Company N.A. increased its position in Chemours by 0.7% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 4,613,843 shares of the specialty chemicals company’s stock worth $73,821,000 after buying an additional 31,548 shares in the last quarter. Finally, State Street Corp increased its position in Chemours by 8.1% in the fourth quarter. State Street Corp now owns 4,287,135 shares of the specialty chemicals company’s stock worth $94,703,000 after buying an additional 321,567 shares in the last quarter. Hedge funds and other institutional investors own 74.71% of the company’s stock.

About Chemours

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

5 Day Chart for NYSE:CC

Receive News & Ratings for Chemours Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Co and related companies with MarketBeat.com's FREE daily email newsletter.